Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pheno Gets Clinical Trial Authorization for PTD802 in Multiple Sclerosis
Details : PTD802 is a novel small molecule therapeutic designed to promote remyelination by inhibiting GPR17. It is being investigated for multiple sclerosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Licensing Agreement